‘Fundamental challenges in Life Sciences similar around the world’

In October 2014, Accenture announced the launch of Accenture Life Sciences Cloud (ALSC) for R&D, a platform developed with Oracle, which aggregates and analyzes data from a variety of sources, speeding up clinical development and drug discovery process .


Mr Kevin Julian, MD, Accenture Accelerated R&D Services

Accenture has also formed a Life Sciences Cloud Coalition with pharmaceutical giants including Eisai, Merck and Pfizer, aiming to bring about innovation and digitally support various R&D functions thereby accelerating drug discovery process while maintaining quality and low costs.

Mr Kevin Julian, MD, Accenture Accelerated R&D Services, spoke exclusively to BioSpectrum's Raj Gunashekar, sharing his views on how the cloud can improve patient outcomes, bolster R&D efficiency, and the future of cloud in Life Sciences organizations.

Q: Tell us the uniqueness of Accenture Life Sciences Cloud.
Mr Kevin Julian: This one started with a client need. One of our clients made a strategic decision to externalize R&D, which prompted the need for a technology platform to aggregate and analyze data from a variety of sources.

Accenture and Oracle partnered to address the client need, and the result of this collaboration laid the foundation of the ALSC.

There are several unique aspects to it including:


Previous 1 3 4 5 Next
1 Comment Comment 1 - 1 of 1

Manjuanth 18 January 2015 at 10:42 PM



Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email